Evidence map›Paper›PMID 28441426›Full record

ArticlePLoS medicine2017

Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data.

Charles C White, Hyun-Sik Yang, Lei Yu, Lori B Chibnik, Robert J Dawe, Jingyun Yang, Hans-Ulrich Klein, Daniel Felsky, Alfredo Ramos-Miguel, Konstantinos Arfanakis and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 3 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The first 25 years of the Northwestern University SuperAging Program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Cognitive resilience to Alzheimer's disease characterized by cell-type abundance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  18. Proteins linking APOE ɛ4 with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  19. Review
  20. Gene specific effects on brain volume and cognition ofmedRxiv : the preprint server for health sciences · 2024
    Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Charles C WhiteProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Hyun-Sik YangProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-8318-0443
Lei YuRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.
Lori B ChibnikProgram in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
Robert J DaweRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.
Jingyun YangRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.
Hans-Ulrich KleinProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Daniel FelskyProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0003-1831-9848
Alfredo Ramos-MiguelDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-6259-1836
Konstantinos ArfanakisRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.ORCID 0000-0001-9705-597X
William G HonerDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Reisa A SperlingCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Julie A SchneiderRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.ORCID 0000-0002-9482-1752
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.
Philip L De JagerProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Broad Institute · USRush University Medical Center · USUniversity of British Columbia · CABrigham and Women's Hospital · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Characterizing the Behavior Profile of Healthy Cognitive AgingR01AG034374 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PATRICIA A BOYLE · 2009 to 2026
$8.8M
Risk Factors, Pathology, and Clinical Expressions of ADRF1AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2014 to 2014
$6.0M
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesRF1AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2016 to 2016
$5.5M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaU01NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2023 to 2025
$3.5M
Multimodal MRI biomarkers of small vessel disease for older persons with and without dementia.UH3NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2018 to 2020
$3.5M
Exploring the Role of the Brain Transcriptome in Cognitive DeclineR01AG036836 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DE JAGER, PHILIP L · 2011 to 2014
$2.9M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaUF1NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2021 to 2021
$2.5M
Epidemiologic Study of TDP-43 Pathology in Aging and DementiaR01AG042210 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 2012 to 2018
$2.4M
NIA NIH HHS K24 AG035007NIA NIH HHS K25 AG041906NIA NIH HHS P30 AG010161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG034374NIA NIH HHS R01 AG036836NIA NIH HHS R01 AG042210NIA NIH HHS RF1 AG015819NIA NIH HHS RF1 AG036042NIA NIH HHS U01 AG046152NINDS NIH HHS U01 NS100599NINDS NIH HHS UF1 NS100599NINDS NIH HHS UH2 NS100599NINDS NIH HHS UH3 NS100599
6 · The paper itself

Abstract

introductionThe molecular underpinnings of the dissociation of cognitive performance and neuropathological burden are poorly understood, and there are currently no known genetic or epigenetic determinants of the dissociation. METHODS AND

findings"Residual cognition" was quantified by regressing out the effects of cerebral pathologies and demographic characteristics on global cognitive performance proximate to death. To identify genes influencing residual cognition, we leveraged neuropathological, genetic, epigenetic, and transcriptional data available for deceased participants of the Religious Orders Study (n = 492) and the Rush Memory and Aging Project (n = 487). Given that our sample size was underpowered to detect genome-wide significance, we applied a multistep approach to identify genes influencing residual cognition, based on our prior observation that independent genetic and epigenetic risk factors can converge on the same locus. In the first step (n = 979), we performed a genome-wide association study with a predefined suggestive p < 10-5, and nine independent loci met this threshold in eight distinct chromosomal regions. Three of the six genes within 100 kb of the lead SNP are expressed in the dorsolateral prefrontal cortex (DLPFC): UNC5C, ENC1, and TMEM106B. In the second step, in the subset of participants with DLPFC DNA methylation data (n = 648), we found that residual cognition was related to differential DNA methylation of UNC5C and ENC1 (false discovery rate < 0.05). In the third step, in the subset of participants with DLPFC RNA sequencing data (n = 469), brain transcription levels of UNC5C and ENC1 were evaluated for their association with residual cognition: RNA levels of both UNC5C (estimated effect = -0.40, 95% CI -0.69 to -0.10, p = 0.0089) and ENC1 (estimated effect = 0.0064, 95% CI 0.0033 to 0.0096, p = 5.7 × 10-5) were associated with residual cognition. In secondary analyses, we explored the mechanism of these associations and found that ENC1 may be related to the previously documented effect of depression on cognitive decline, while UNC5C may alter the composition of presynaptic terminals. Of note, the TMEM106B allele identified in the first step as being associated with better residual cognition is in strong linkage disequilibrium with rs1990622A (r2 = 0.66), a previously identified protective allele for TDP-43 proteinopathy. Limitations include the small sample size for the genetic analysis, which was underpowered to detect genome-wide significance, the evaluation being limited to a single cortical region for epigenetic and transcriptomic data, and the use of categorical measures for certain non-amyloid-plaque, non-neurofibrillary-tangle neuropathologies.

conclusionsThrough a multistep analysis of cognitive, neuropathological, genomic, epigenomic, and transcriptomic data, we identified ENC1 and UNC5C as genes with convergent genetic, epigenetic, and transcriptomic evidence supporting a potential role in the dissociation of cognition and neuropathology in an aging population, and we expanded our understanding of the TMEM106B haplotype that is protective against TDP-43 proteinopathy.

Indexed as

AgedAged, 80 and overAgingAllelesAlzheimer DiseaseBrainCognitionCognition DisordersDepressionDNA MethylationEpigenesis, GeneticFemaleGenome-Wide Association StudyGenotypeHumansLinkage Disequilibriumectodermal-neural cortex 1 proteinMembrane ProteinsMicrofilament ProteinsNerve Tissue ProteinsNetrin ReceptorsNeuropeptidesNuclear ProteinsReceptors, Cell SurfaceRNATMEM106B protein, humanUNC5C protein, human

Identifiers

PMID28441426
PMCPMC5404753
OpenAlexW2607994886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.